Nanological
Nanological is a Deep Tech diagnostics company founded by researchers from the Spanish National Research Council (CSIC). Their proprietary platform, built on over a decade of research in optomechanical biosensing and protected by international patents, focuses on rapid sepsis diagnostics. Their product, SOMIA, uses AI-powered sensing to identify pathogens directly from blood in under 30 minutes, without culture or labeling. This enables early, targeted treatment and significantly increases patient survival rates, addressing the critical need for faster sepsis identification compared to traditional methods that take days. The company brings together scientists, engineers, and business professionals to translate scientific breakthroughs into clinical solutions.
Nanological
Nanological is a Deep Tech diagnostics company founded by researchers from the Spanish National Research Council (CSIC). Their proprietary platform, built on over a decade of research in optomechanical biosensing and protected by international patents, focuses on rapid sepsis diagnostics. Their product, SOMIA, uses AI-powered sensing to identify pathogens directly from blood in under 30 minutes, without culture or labeling. This enables early, targeted treatment and significantly increases patient survival rates, addressing the critical need for faster sepsis identification compared to traditional methods that take days. The company brings together scientists, engineers, and business professionals to translate scientific breakthroughs into clinical solutions.
TL;DR
Headquarters: Madrid, Spain
Founded: 2021
Product: SOMIA — point-of-care sepsis diagnostic platform
Key tech: Optomechanical biosensing, microfluidics, AI
Time-to-result: <30 minutes (pathogen ID from whole blood)
Recent funding: Seed round (Nov 22, 2023) and CDTI grant (Sep 29, 2023)
Company Overview
Problem Domain
Rapid sepsis diagnostics / pathogen identification from blood
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
€325,000
CDTI grant for product development (NEOTEC-related)
€600,000
Seed round announced Nov 22, 2023
Investor Signal
“Receieved institutional grant support (CDTI) and seed investment from a healthcare/VC investor (Clave Capital) indicating public and private backing for commercialization”